Overview

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for post-operative nausea and vomiting (PONV) treated with oral aprepitant with or without transdermal scopolamine preoperatively.
Phase:
N/A
Details
Lead Sponsor:
Drexel University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Aprepitant
Butylscopolammonium Bromide
Fosaprepitant
Scopolamine
Scopolamine Hydrobromide